Greece widens Pedmarqsi withdrawal with three further batches of 80 mg/ml infusion
Greek medicines agency EOF has pulled three more lots of Pedmarqsi from the market, but the public listing gives no reason and no commercial detail.
Greece's medicines agency, EOF, has widened its withdrawal of Pedmarqsi 80 mg/ml, an infusion formulation, to cover three more production lots: 489588, 493006 and 497199.
The notice is dated 6 November 2026 and carries protocol number 136391. It is framed as an extension of an earlier action on the same product, not a fresh one. The listing does not say how many batches the first action covered.
The public entry is brief and links to the full decision. It does not give the reason for the withdrawal, the defect or risk behind it, or the steps required of pharmacies, wholesalers and hospitals. It also does not say whether the action reaches patients or stops at the distribution chain.
Nothing in the listing allows the commercial effect to be measured. It gives no sales figures, no volumes tied to the three lots, no word on supply continuity, and no named marketing authorisation holder. As general context, a recall limited to specific batches is narrower than pulling a product altogether, and the listing does not suggest the latter.
Why it matters
- The extension adds three named lots to an existing Greek action on Pedmarqsi 80 mg/ml, so the affected scope is growing.
- The reason for the recall and its patient-level reach are not in the public listing, so the commercial and supply impact cannot yet be sized.
- Stock reconciliation across all affected lots depends on the full EOF decision (protocol 136391) and the earlier notice.
Written by CompePharma's editorial system from the official record. AI-assisted; check the source before acting. Not investment advice.
Medline details repair and replace programme for recalled beds, rails, mattresses and accessories
Cingulate nearly done with manufacturing fixes for ADHD drug CTx-1301 ahead of NDA resubmission
Bluejay completes SYMON-II enrolment for Symphony IL-6 sepsis test, eyes 510(k) filing in H1 2027
Philips recalls Azurion 7 M20 over software faults that can halt imaging or stand movement
Game Changer Products recalls all lots of 10 Day Forecast capsules over hidden sildenafil
